Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nexavar in BRAF-mutated Refractory Solid Tumors
NCT02691780Withdrawn
- Sponsor
- Samsung Medical Center
- Start
- Dec 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sorafenib in solid tumor, sponsored by Samsung Medical Center. Primary endpoint: Progression-Free Survival at 24 months. Planned start Dec 2016; status: withdrawn.
02
Drugs
sorafenib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02691780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02691780.